Atypical course of COVID-19 in patient with Bruton agammaglobulinemia

J Infect Dev Ctries. 2020 Nov 30;14(11):1248-1251. doi: 10.3855/jidc.13840.

Abstract

We present atypical course of the novel coronavirus disease (COVID-19) in 34-year man with Bruton agammaglobulinemia. The patient was successfully treated by a combination of available drugs, including convalescent plasma and interleukin-6 (IL-6) inhibitor.

Keywords: COVID-19; IL-6; agammaglobulinemia; convalescent plasma; inhibitor.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Agammaglobulinaemia Tyrosine Kinase
  • Agammaglobulinemia / complications*
  • Agammaglobulinemia / drug therapy
  • COVID-19 / complications*
  • COVID-19 Drug Treatment
  • Disease Progression
  • Humans
  • Immunoglobulins, Intravenous / administration & dosage
  • Male
  • SARS-CoV-2

Substances

  • Immunoglobulins, Intravenous
  • Agammaglobulinaemia Tyrosine Kinase
  • BTK protein, human